ClinicalTrials.gg
CompletedNCT02152761Updated Aug 19, 2020Results posted

Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery

A Phase 2 interventional study of bimagrumab and placebo in Muscle Wasting (Atrophy) After Hip Fracture Surgery, sponsored by Novartis Pharmaceuticals. Completed at 53 sites in 19 countries. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2020-08-19.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
251
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Muscular Atrophy by Novartis — 1 open to participants now, 2 under way, 1 of them phase 3. Muscular Atrophy · Novartis.

Enrollment
Largest of 12
251 · median 112
Started
2014
with 1 other
Phase 2
4 of 13
none open now
Registered
3rd of 13
by date

Among the 13 studies in Muscular Atrophy by Novartis, this one has the largest enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2014, is one of 4 in phase 2, and was the 3rd registered.

Muscular Atrophy

413 studies on the registry are indexed under Muscular Atrophy; 77 are open to participants now.

Browse Muscular Atrophy studies →

Open to participants now

1 of the 13 studies in Muscular Atrophy by Novartis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 52 Muscular Atrophy studies recruiting now, 25 (48%) set no upper age limit and 13 (25%) stop at 75 or younger; 4 take children under 18; 17 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Muscular Atrophy by Novartis, or all of them as a file.
02

Study summary

The purpose of this study was to assess if bimagrumab is safe and effective in patients with muscle wasting (atrophy) after hip fracture surgery.

03

Conditions studied

  • Muscle Wasting (Atrophy) After Hip Fracture Surgery

Keywords

  • bimagrumab
  • BYM338
  • hip fracture
  • elderly
  • controlled clinical trial
  • randomized
  • muscle wasting
  • atrophy
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Must have X-ray confirmed successful hip fracture repair; Must have completed surgical wound healing; Ability to walk a specified distance with or without a walking aid; Must weigh at least 35 kg.

Exclusion criteria

Exclusion Criteria:

Must not have history of any other lower limb fractures in the past 6 months; Must not have certain cardiovascular conditions; Must not have a chronic active infection (e.g. , or C, etc); Must not have used high-dose medications for at least 3 months in the past year;

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
251 participants (actual)

Study arms

  • Experimental
    bimagrumab 700 mg

    Approximately 70 patients who met all inclusion criteria and none of the exclusion criteria were treated with the bimagrumab high dose administered via intravenous infusion starting Day 1 until Week 20

    Drug: bimagrumab

  • Experimental
    bimagrumab 210 mg

    Approximately 70 patients who met all inclusion criteria and none of the exclusion criteria were treated with the bimagrumab medium dose administered via intravenous infusion starting Day 1 until Week 20

    Drug: bimagrumab

  • Placebo comparator
    placebo

    Approximately 70 patients who met all inclusion criteria and none of the exclusion criteria received matching placbo administered via intravenous infusion starting Day 1 until Week 20

    Other: placebo

  • Experimental
    Bimagrumab 70 mg

    Approximately 35 patients who met all inclusion criteria and none of the exclusion criteria were treated with bimagrumad low dose administered via intravenous infusion starting Day 1 until Week 20

    Drug: bimagrumab

Interventions

  • Bimagrumab was administered as intravenous infusion starting on Day 1 until week 20.

    Also known as: BYM338

  • Otherplacebo

    Matching placebo was administered as intravenous infusion starting on Day 1 until week 20.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Total Lean Body Mass Measured by DXA (Dual-energy X-ray Absorptiometry) at Weeks 12 and 24

    Mixed Model for Repeated Measures (MMRM) of change from baseline in total LBM (kg) by treatment and visit To assess dose-response relationship of bimagrumab and facilitate an adequate dose selection for future phase III studies, without the need for supportive data from another dose-response finding study, at least three doses were required, ranging from a non-effective or minimally effective dose to a dose where maximal efficacy is expected. Original study was initiated with only two doses of bimagrumab, therefore, a lower dose arm of 70mg has been added to this study with Amendment 2, changing the randomization ratio from 1:1:1 to 2:1:2:2 to either placebo, bimagrumab 70mg, bimagrumab 210mg, or bimagrumab 700mg. Since the 70mg dose was expected to show suboptimal efficacy and fewer patients were randomized to this group, it was used only for dose response modelling and not for hypothesis testing. Consequently, no efficacy evaluations for the bimagrumab 70mg Arm were performed

    Time frame: baseline, weeks 12 and 24

Secondary outcomes

  1. Change From Baseline in Gait Speed at Week 24 (Meters/Sec)

    Mixed Model for Repeated Measures (MMRM) of change from baseline in derived gait speed (m/sec) by treatment and visit To assess dose-response relationship of bimagrumab and facilitate an adequate dose selection for future phase III studies, without the need for supportive data from another dose-response finding study, at least 3 doses were required, ranging from a non-effective or minimally effective dose to a dose where maximal efficacy is expected. Original study was initiated with only two doses of bimagrumab, therefore, a lower dose arm of 70mg was added to this study with Amendment 2, changing the randomization ratio from 1:1:1 to 2:1:2:2 to either placebo, bimagrumab 70mg, bimagrumab 210mg, or bimagrumab 700mg. Since the 70mg dose was expected to show suboptimal efficacy and fewer patients were randomized to this group, it was used only for dose response modelling and not for hypothesis testing. Consequently, no efficacy evaluations for the bimagrumab 70mg Arm were performed

    Time frame: Baseline, Week 24

  2. Change From Baseline in Short Physical Performance Battery at Weeks 24

    MMRM change from baseline in total score by treatment \& visit to Week 24 in physical performance measured by Short Physical Performance Battery (SPPB) that evaluates lower extremity function. Score range is 0 (worst performance) to 12 (best) to assess dose-response relationship of bimagrumab \& facilitate adequate dose selection for future phase III studies, without need for supportive data from another dose-response finding study, at least 3 doses were required, ranging from non- or minimally effective dose to a dose where maximal efficacy was expected. Original study was initiated with only 2 doses, therefore, lower 70mg arm was added to this study, changing randomization ratio from 1:1:1 to 2:1:2:2 to either placebo, bimagrumab 70mg, 210mg, or 700mg. Since 70mg dose was expected to show suboptimal efficacy, fewer patients were randomized to this group \& it was used only for dose response modelling \& not hypothesis testing. Consequently, no efficacy evaluation for 70mg were performed

    Time frame: Week 24

  3. Incidence of Falls up to Week 48

    Group falls rate The frequency of having at least one fall up to Week 48 was summarized by treatment groups Incidence of falls was calculated for each arm up to Week 48. The ratio of these fall rates versus Placebo were calculated and presented as the Falls Rate Ratio. As mentioned in comment 5.1 above, the Falls Rate Ratio for Placebo does not apply because it would entail comparing the group to itself

    Time frame: Up to Week 48

07

Results

Posted Aug 19, 2020
Limitations and caveats
As there were no statistically significant improvements in functional measures (i.e. gait speed, SPPB) at week 24, the need to test for sustained improvement at wk 48 became irrelevant. So, wk 48 treatment differences were not evaluated

Participant flow

384 subjects were screened, and 252 subjects completed Screening period. One was lost to follow-up after screening and did not attend any visits for treatment epoch therefore, 251 were recruited to study. 2 subjects died during Screening epoch (1 was reported as discontinued and 1 was reported as a screen failure)

Epoch: Treatment Epoch
Participant flow — Epoch: Treatment Epoch
MilestoneBimagrumab 700 mgBimagrumab 210 mgBimagrumab 70 mgPlacebo
Started75703472
Completed64502964
Not completed112058
Withdrew: Technical problems0001
Withdrew: Lost to follow-up0200
Withdrew: Withdrawal by subject7835
Withdrew: Adverse event3612
Withdrew: Death0310
Withdrew: Non-compliance with treatment1100
Epoch: Post-treatment Follow-up Epoch
Participant flow — Epoch: Post-treatment Follow-up Epoch
MilestoneBimagrumab 700 mgBimagrumab 210 mgBimagrumab 70 mgPlacebo
Started67543068
Completed63473066
Not completed4702
Withdrew: Withdrawal by subject1301
Withdrew: Lost to follow-up1400
Withdrew: Adverse event1000
Withdrew: Death1001

Outcome measures

PrimaryChange From Baseline in Total Lean Body Mass Measured by DXA (Dual-energy X-ray Absorptiometry) at Weeks 12 and 24

Mixed Model for Repeated Measures (MMRM) of change from baseline in total LBM (kg) by treatment and visit To assess dose-response relationship of bimagrumab and facilitate an adequate dose selection for future phase III studies, without the need for supportive data from another dose-response finding study, at least three doses were required, ranging from a non-effective or minimally effective dose to a dose where maximal efficacy is expected. Original study was initiated with only two doses of bimagrumab, therefore, a lower dose arm of 70mg has been added to this study with Amendment 2, changing the randomization ratio from 1:1:1 to 2:1:2:2 to either placebo, bimagrumab 70mg, bimagrumab 210mg, or bimagrumab 700mg. Since the 70mg dose was expected to show suboptimal efficacy and fewer patients were randomized to this group, it was used only for dose response modelling and not for hypothesis testing. Consequently, no efficacy evaluations for the bimagrumab 70mg Arm were performed

Time frame:
baseline, weeks 12 and 24
Reported as:
Least squares mean · kg
Change From Baseline in Total Lean Body Mass Measured by DXA (Dual-energy X-ray Absorptiometry) at Weeks 12 and 24
kgBimagrumab 700 mgBimagrumab 210 mgActive Total Efficacy (AT:E)Placebo
week 121.066 ± 0.01071.052 ± 0.01091.059 ± 0.00961.009 ± 0.0103
week 241.064 ± 0.01131.042 ± 0.01151.053 ± 0.01010.996 ± 0.0109
Statistical analysis
  • Bimagrumab 700 mg vs Placebo · Mixed Models Analysis · p = <.0001 · Treatment group ratio (bym - placebo): 1.057 · 95% CI 1.037 to 1.076Holm-Bonferroni method: Used to adjust the Type I error for two comparisons (BYM338 700 mg/Placebo) at Week 24. No control for multiplicity was made at Week 12.
  • Bimagrumab 210 mg vs Placebo · Mixed Models Analysis · p = <.0001 · Treatment group rratio (bym - placebo): 1.043 · 95% CI 1.024 to 1.064Holm-Bonferroni method: Used to adjust the Type I error for two comparisons (BYM338 700 mg/Placebo) at Week 24. No control for multiplicity was made at Week 12.
SecondaryChange From Baseline in Gait Speed at Week 24 (Meters/Sec)

Mixed Model for Repeated Measures (MMRM) of change from baseline in derived gait speed (m/sec) by treatment and visit To assess dose-response relationship of bimagrumab and facilitate an adequate dose selection for future phase III studies, without the need for supportive data from another dose-response finding study, at least 3 doses were required, ranging from a non-effective or minimally effective dose to a dose where maximal efficacy is expected. Original study was initiated with only two doses of bimagrumab, therefore, a lower dose arm of 70mg was added to this study with Amendment 2, changing the randomization ratio from 1:1:1 to 2:1:2:2 to either placebo, bimagrumab 70mg, bimagrumab 210mg, or bimagrumab 700mg. Since the 70mg dose was expected to show suboptimal efficacy and fewer patients were randomized to this group, it was used only for dose response modelling and not for hypothesis testing. Consequently, no efficacy evaluations for the bimagrumab 70mg Arm were performed

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · meters per second
Change From Baseline in Gait Speed at Week 24 (Meters/Sec)
meters per secondBimagrumab 700 mgBimagrumab 210 mgPlacebo
Change From Baseline in Gait Speed at Week 24 (Meters/Sec)0.268 ± 0.05990.350 ± 0.06170.339 ± 0.0607
Statistical analysis
  • Bimagrumab 700 mg vs Placebo · Mixed Models Analysis · p = 0.1829 (Treatment Difference (BYM-Placebo)) · Ls mean of treatment difference: -0.071 · 95% CI -0.175 to 0.034
  • Bimagrumab 210 mg vs Placebo · Mixed Models Analysis · p = 0.8365 · Ls mean of treatment difference: 0.011 · 95% CI -0.096 to 0.119
SecondaryChange From Baseline in Short Physical Performance Battery at Weeks 24

MMRM change from baseline in total score by treatment \& visit to Week 24 in physical performance measured by Short Physical Performance Battery (SPPB) that evaluates lower extremity function. Score range is 0 (worst performance) to 12 (best) to assess dose-response relationship of bimagrumab \& facilitate adequate dose selection for future phase III studies, without need for supportive data from another dose-response finding study, at least 3 doses were required, ranging from non- or minimally effective dose to a dose where maximal efficacy was expected. Original study was initiated with only 2 doses, therefore, lower 70mg arm was added to this study, changing randomization ratio from 1:1:1 to 2:1:2:2 to either placebo, bimagrumab 70mg, 210mg, or 700mg. Since 70mg dose was expected to show suboptimal efficacy, fewer patients were randomized to this group \& it was used only for dose response modelling \& not hypothesis testing. Consequently, no efficacy evaluation for 70mg were performed

Time frame:
Week 24
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Short Physical Performance Battery at Weeks 24
scores on a scaleBimagrumab 700 mgBimagrumab 210 mgPlacebo
Change From Baseline in Short Physical Performance Battery at Weeks 242.331 ± 0.54363.535 ± 0.56232.702 ± 0.5516
Statistical analysis
  • Bimagrumab 700 mg vs Placebo · Mixed Models Analysis · p = 0.5802 · Ls mean of treatment difference: -0.371 · 95% CI -1.311 to 1.053
  • Bimagrumab 210 mg vs Placebo · Mixed Models Analysis · p = 0.0913 · Ls mean of the treatment difference: 0.833 · 95% CI -0.135 to 1.801
SecondaryIncidence of Falls up to Week 48

Group falls rate The frequency of having at least one fall up to Week 48 was summarized by treatment groups Incidence of falls was calculated for each arm up to Week 48. The ratio of these fall rates versus Placebo were calculated and presented as the Falls Rate Ratio. As mentioned in comment 5.1 above, the Falls Rate Ratio for Placebo does not apply because it would entail comparing the group to itself

Time frame:
Up to Week 48
Reported as:
Least squares mean · Number of Falls per week
Incidence of Falls up to Week 48
Number of Falls per weekBimagrumab 700 mgBimagrumab 210 mgBimagrumab 70mgPlacebo
Incidence of Falls up to Week 480.31 (0.14 to 0.70)0.45 (0.20 to 0.99)0.36 (0.13 to 0.97)0.29 (0.13 to 0.64)
Statistical analysis
  • Bimagrumab 700 mg vs Placebo · Negative binomial regression · p = 0.8353 · Falls rate ratio: 1.08 · 95% CI 0.53 to 2.21
  • Bimagrumab 210 mg vs Placebo · Negative binomial regression · p = 0.2015 · Falls rate ratio: 1.58 · 95% CI 0.78 to 3.18
  • Bimagrumab 70mg vs Placebo · Negative binomial regression · p = 0.3999 · Falls rate ratio: 1.25 · 95% CI 0.52 to 3.00

Adverse events

Collected over AEs and SAEs were collected for the maximum duration of treatment and follow up for a participant per protocol for approximately 48 weeks. All cause mortality (deaths) was collected from First Patient First Visit (FPFV) to Last Patient Last Visit (LPLV) up to a maximum of 48 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BYM338 700 mg1/75 (1.3%)15/75 (20%)47/75 (62.7%)
BYM338 210 mg3/69 (4.3%)17/69 (24.6%)34/69 (49.3%)
BYM338 70 mg1/34 (2.9%)9/34 (26.5%)15/34 (44.1%)
AT:S5/178 (2.8%)41/178 (23%)96/178 (53.9%)
Placebo1/72 (1.4%)9/72 (12.5%)30/72 (41.7%)
Most frequent serious events
Showing 10 of 65
Most frequent serious events
EventBYM338 700 mgBYM338 210 mgBYM338 70 mgAT:SPlacebo
AnaemiaBlood and lymphatic system disorders0/750/691/341/1780/72
Atrial fibrillationCardiac disorders1/751/691/343/1780/72
Cardiac failureCardiac disorders0/750/691/341/1780/72
Retinal haemorrhageEye disorders0/750/691/341/1780/72
HaematocheziaGastrointestinal disorders0/750/691/341/1780/72
Oedema peripheralGeneral disorders0/750/691/341/1780/72
BronchitisInfections and infestations1/751/691/343/1780/72
PneumoniaInfections and infestations0/751/691/342/1781/72
Urinary tract infectionInfections and infestations0/750/691/341/1780/72
UrosepsisInfections and infestations0/750/691/341/1780/72
Most frequent other events
Showing 10 of 16
Most frequent other events
EventBYM338 700 mgBYM338 210 mgBYM338 70 mgAT:SPlacebo
Muscle spasmsMusculoskeletal and connective tissue disorders12/7517/692/3431/1786/72
FallInjury, poisoning and procedural complications14/7512/696/3432/17813/72
ArthralgiaMusculoskeletal and connective tissue disorders8/756/695/3419/1785/72
Oedema peripheralGeneral disorders9/753/691/3413/1784/72
Urinary tract infectionInfections and infestations8/753/692/3413/1782/72
DiarrhoeaGastrointestinal disorders7/754/690/3411/1781/72
Back painMusculoskeletal and connective tissue disorders4/755/691/3410/1782/72
ContusionInjury, poisoning and procedural complications3/751/690/344/1785/72
NasopharyngitisInfections and infestations5/751/692/348/1782/72
BronchitisInfections and infestations0/751/692/343/1781/72

Baseline characteristics

The Full Analysis Set (FAS) used for all efficacy analyses consists of all randomized patients who received at least one dose of treatment after randomization and had at least one post-dose efficacy assessment. Patients who were randomized in error were excluded. Patients were analyzed according to treatment they were assigned to at randomization.

Age, Continuous
Age, Continuous(years)Bimagrumab 700 mgBimagrumab 210 mgBimagrumab 70 mgPlaceboTotal
Mean76.1 ± 8.5874.8 ± 8.9476.1 ± 8.5976.4 ± 7.8875.8 ± 8.46
Age, Customized
Age, Customized(Participants)Bimagrumab 700 mgBimagrumab 210 mgBimagrumab 70 mgPlaceboTotal
< 65 years994325
65 - 74 years2223102782
75 - 84 years30261632104
=>85 years141141039
Sex: Female, Male
Sex: Female, Male(Participants)Bimagrumab 700 mgBimagrumab 210 mgBimagrumab 70 mgPlaceboTotal
Female54482153176
Male2121131974
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Bimagrumab 700 mgBimagrumab 210 mgBimagrumab 70 mgPlaceboTotal
Caucasian57582653194
Black00000
Asian13861744
Other432211
Native American10001
08

Study locations

53 sites
  • Novartis Investigative Site
    Phoenix, Arizona 85023, United States
  • Novartis Investigative Site
    El Cajon, California 92020, United States
  • Novartis Investigative Site
    Denver, Colorado 80210, United States
  • Novartis Investigative Site
    Gainesville, Georgia 30501, United States
  • Novartis Investigative Site
    Rochester, Minnesota 55905, United States
  • Novartis Investigative Site
    New York, New York 10021, United States
  • Novartis Investigative Site
    Ciudad Autonoma de Bs As, C1128AAF, Argentina
  • Novartis Investigative Site
    Bedford Park, South Australia 5041, Australia
  • Novartis Investigative Site
    Graz, 80 10, Austria
  • Novartis Investigative Site
    Brugge, 8000, Belgium
  • Novartis Investigative Site
    Genk, 3600, Belgium
  • Novartis Investigative Site
    Gent, 9000, Belgium
  • Novartis Investigative Site
    Santiago, 838 0456, Chile
  • Novartis Investigative Site
    Cali, Valle Del Cauca, Colombia
  • Novartis Investigative Site
    Barranquilla, Colombia
  • Novartis Investigative Site
    Brno, Czech Republic 66250, Czechia
  • Novartis Investigative Site
    Hradec Kralove, Czech Republic 500 05, Czechia
  • Novartis Investigative Site
    Pardubice, Czech Republic 532 03, Czechia
  • Novartis Investigative Site
    Plzen, Czech Republic 30450, Czechia
  • Novartis Investigative Site
    Praha 5, Czech Republic 150 06, Czechia
  • Novartis Investigative Site
    Praha 10, 100 34, Czechia
  • Novartis Investigative Site
    Lille Cedex, 59037, France
  • Novartis Investigative Site
    Montpellier, 34295, France
  • Novartis Investigative Site
    Bad Abbach, 93077, Germany
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Magdeburg, 39110, Germany
  • Novartis Investigative Site
    Würzburg, 97074, Germany
  • Novartis Investigative Site
    Budapest, 1062, Hungary
  • Novartis Investigative Site
    Budapest, 1125, Hungary
  • Novartis Investigative Site
    Hatvan, 3000, Hungary
  • Novartis Investigative Site
    Nishinomiya-city, Hyogo 662-0918, Japan
  • Novartis Investigative Site
    Kamakura-city, Kanagawa 247-8533, Japan
  • Novartis Investigative Site
    Kochi-city, Kochi 780-8522, Japan
  • Novartis Investigative Site
    Kumamoto-city, Kumamoto 862-0976, Japan
  • Novartis Investigative Site
    Okayama city, Okayama 701-1192, Japan
  • Novartis Investigative Site
    Toyama-City, Toyama 939-8511, Japan
  • Novartis Investigative Site
    Aguascalientes, 20127, Mexico
  • Novartis Investigative Site
    San Luis Potosi, 78200, Mexico
  • Novartis Investigative Site
    Saint-Petersburg, 196143, Russian Federation
  • Novartis Investigative Site
    Sestroretsk, 197706, Russian Federation
  • Novartis Investigative Site
    St.- Petersburg, 190103, Russian Federation
  • Novartis Investigative Site
    Yaroslavl, 150003, Russian Federation
  • Novartis Investigative Site
    Sevilla, Andalucia 41014, Spain
  • Novartis Investigative Site
    Barcelona, Catalunya 08035, Spain
  • Novartis Investigative Site
    Barcelona, Catalunya 08036, Spain
  • Novartis Investigative Site
    Madrid, 28049, Spain
  • Novartis Investigative Site
    Genève 14, 1211, Switzerland
  • Novartis Investigative Site
    Kaohsiung, 82445, Taiwan
  • Novartis Investigative Site
    Taipei, 11217, Taiwan
  • Novartis Investigative Site
    Taoyuan, 33305, Taiwan
  • Novartis Investigative Site
    Istanbul, 34093, Turkey
  • Novartis Investigative Site
    Izmir, 35040, Turkey
  • Novartis Investigative Site
    Bath, BA1 3NG, United Kingdom
09

References and documents

Publications

  • Hofbauer LC, Witvrouw R, Varga Z, Shiota N, Cremer M, Tanko LB, Rooks D, Auberson LZ, Arkuszewski M, Fretault N, Schubert-Tennigkeit AA, Papanicolaou DA, Recknor C. Bimagrumab to improve recovery after hip fracture in older adults: a multicentre, double-blind, randomised, parallel-group, placebo-controlled, phase 2a/b trial. Lancet Healthy Longev. 2021 May;2(5):e263-e274. doi: 10.1016/S2666-7568(21)00084-2. PubMed 36098133 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2014 to primary completion in May 2018, 43 months.

Results were first posted in Aug 2020, 2 years 3 months after primary completion. A results delay was requested in Oct 2018.

Of 19 phase 2 interventional studies under Muscular Atrophy, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 43. This study's 43 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2014
First posted
Jun 2, 2014
StartActual
Sep 16, 2014
Primary completionActual
May 14, 2018
CompletionActual
Oct 25, 2018
Results delay requested
Oct 10, 2018
Results first posted
Aug 19, 2020
Last update
Aug 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02152761
Responsible party
Sponsor
First posted
Jun 2, 2014
Start date
Sep 16, 2014
Primary completion
May 14, 2018
Completion
Oct 25, 2018
Results posted
Aug 19, 2020
Last update
Aug 19, 2020

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimagrumab

Start the discussion